The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Study links 'bad cholesterol' to dementia. Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, and statins could add to the benefit, according to a just-published study.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.

“In November 2022, a study revealed that blood pressure drugs that stimulate type 2 and 4 angiotensin II receptors in the brain were associated with lower rates of dementia among new users of ...

Ozempic and Similar Drugs Could Help Ward Off Dementia, Study Suggests According to the study researchers, however, there’s still a lot we don’t know about exactly how GLP-1 drugs change ...